To evaluate the safety and efficacy of cabergoline in men with erectile dysfunction (ED) who did not respond to sildenafil. Four hundred two sildenafil nonresponders aged from 21 to 59 years were included in the study. Patients were randomly divided into group 1, those who received 0.5-1 mg cabergoline weekly for 6 months and group 2, who received placebo for the same period. They underwent preliminary assessment, including medical and sexual history, self-administered International Index of Erectile Function (IIEF) and intravaginal ejaculatory latency time (IVELT) evaluation. Standard biochemistry and hematological laboratory tests, and measurement of serum testosterone and prolactin levels were also carried out. When indicated, other tests were used to establish the diagnosis of vasculogenic and neurogenic ED, including penile color duplex Doppler ultrasonography, pudendal nerve conduction test and impaired sensory-evoked potentials studies. The efficacy of two treatments was assessed every 2 weeks during treatment, at the end of the study, using responses to IIEF, IVELT evaluation, mean intercourse satisfaction domain, mean weekly coitus episodes and adverse drug effects. The trial was completed by 370 (92%) men. Positive clinical results were seen in 31.2% of patients in the cabergoline group compared with 7.1% of patients in the placebo group (P ¼ 0.04). The mean weekly intercourse episodes increased from pretreatment values of 1.4 and 1.2 to 2.2 and 1.4, for cabergoline and placebo, respectively (P ¼ 0.04). Baseline mean intercourse satisfaction domain values of IIEF 10 and 11 reached to 15 and 10 at 6-month treatment in groups 1 and 2, respectively (P ¼ 0.04). The IVELT after cabergoline and placebo gradually increased from 98 and 101 s to approximately 242 and 116 s, respectively (P ¼ 0.001). More drug-related adverse effects occurred in cabergoline group and 12 (5.9%) had to discontinue treatment (P ¼ 0.001). Cabergoline is moderately effective salvage therapy for sildenafil nonresponse. Further studies with different dosages and treatment regimens are necessary to draw final conclusions on the efficacy of this drug in ED.
Introduction
Normal erectile function relies on the coordination of neurogenic, psychologic, endocrine and vascular factors. Sildenafil citrate, an orally administered phosphodiesterase-5 (PDE-5) inhibitor generally used to treat erectile dysfunction (ED). It is the first oral medication to exhibit significant and reliable efficacy in most patients with ED. 1 Nowadays more than 15 million men have used this medication with primary care specialists writing more than half of these prescriptions. 2, 3 Marketing data worldwide demonstrated that dropout rates for sildenafil are as high as 50% of patients treated. 4 In spite of its effectiveness, yet, approximately 30-50% of subjects receiving sildenafil do not satisfactorily respond to therapy. 5 Proposed rationales for treatment discontinuation include variations in motivation in patients incorporated in the clinical trials and those of the everyday practice, lack of reimbursement, failure to recognize patients expectations from sexual life, 6 lack of a definitive cure, low efficacy, fear of adverse events and need for sexual intercourse scheduling. 7, 8 A panel of experts at the first International Consultation on Erectile Dysfunction recommended oral agents as first line treatment for ED independent of etiology.
The central nervous system controls sexual behavior and related sexual responses, for example erection and ejaculation in males. Pharmacological researches have focused on the role of neurotransmitters and neuropeptides involved in this central control. 10 Particular attention has been made to dopamine (DA) and, hence, to the dopaminergic D 1 /D 2 receptor agonists. At least six different forms of the DA receptors cloned from the brain have been reported. The D 1 class of DA receptor has been divided into D 1 and D 5 receptor subtypes and the D 2 class comprises D 2S -, D 2L -, D 3 -, and D 4 -receptor subtypes. 11, 12 Dopamine-mediated improvement of sexual behavior was first recognized when administration of l-dopa (3,4-dihydroxyl-phenylalanine), the precursor to DA, to men suffering from Parkinson's disease resulted in increased libido and sexual potency. [13] [14] [15] In addition to enhancing the consummatory phase of sexual behavior, DA agonists also enhanced psychogenic erections and sexual motivation. 16 Other DA agonists, including apomorphine (a D 1 /D 2 DA receptor agonist), have also been used to potentiate human erectile function. 17 Central sexual input from the forebrain and peripheral sexual stimuli are integrated in the medial preoptic area and the paraventricular nucleus of the hypothalamus and transmitted via the spinal cord and peripheral autonomic nerves to the penis. Both structures can be activated by dopaminergic agents. 18 The beneficial effect of apomorphine in ED is marginal. In a placebo-controlled study 48-53% of patients with ED achieved and maintained an erection firm enough for intercourse as compared with 35% for placebo. 19 In another study, the global response to the apomorphine amounted to 26.1%. 20 We need more safe and effective drugs launched specifically for the treatment of ED, especially in nonresponders to PDE-5 inhibitors.
The ergot alkaloids, 21, 22 derivatives of lysergic acid or ergoline structures show a broad range of pharmacological activities. Many of them are DA D 2 receptor agonists, 23, 24 but some ergoline derivatives also interact with serotonin receptors [25] [26] [27] and adrenoceptors 28, 29 with very high affinities. Cabergoline is a selective D 2 agonist whereas apomorphine is a non-specific D 1 /D 2 agonist. With its highly specific D 2 receptor agonism and its favorable adverse effect profile, cabergoline may turn out to be particularly suitable for this indication. Its elimination half-life has been estimated as about 65-110 h, 30 and therefore may provide fairly steady dopaminergic stimulation. It is generally assumed that selective serotonin reuptake inhibitors sexual side effects are related to increased central 5-hydroxytryptamine (5-HT, serotonin) neurotransmission and activation of postsynaptic 5-HT receptors. 31, 32 Selective serotonin reuptake inhibitors (paroxetine, fluoxetine, sertraline) are reported to be effective for treating premature ejaculation. 33, 34 As recently published, cabergoline caused potent 5-HT receptor activation. 35 Receptor-binding studies indicate that cabergoline has also low affinity for a 1 -and a 2 -adrenergic receptors. 36 It has been suggested that central adrenergic receptors promote sexual function. 37 Although there are no published reports on the use of cabergoline as an ED pharmacotherapy, several reports show that cabergoline is able to ameliorate disorders associated with DA deficiency and hence is an appropriate candidate for this trial. [38] [39] [40] [41] [42] To our knowledge this the first study to assess the efficacy of cabergoline in nonresponders to sildenafil.
Materials and methods
This study comprised 486 married men (aged 21-59 years) with ED and their wives. They were referred to 1 urologist (MRS) from primary care physicians or addressed themselves disappointed by the results of sildenafil from February 2002 to March 2005. The diagnosis of ED was established according to the National Institute of Health statement on ED. 43 All patients were given a sildenafil instruction/safety sheet prior to including the study. The instruction sheet emphasized the timing of sildenafil administration (45 min-2 h prior to sexual stimulation) as well as the absolute need for sexual stimulation, such as visual stimulation, foreplay and hugging. In addition, the instruction sheet stressed that sildenafil should be used 2-3 h after a low-fat meal. Finally, the sheet also emphasized that outcomes tend to get better after six to eight attempts and success is often dose dependent. The office visit consisted of physical examination and patient reinstruction following a review of patient history and risk factors. The starting dose in all patients was 50 mg. They were instructed to rapidly increase the dose from the 50 to 100 mg after one attempt if the initial treatment was not satisfactory and there were no adverse reactions, but not to exceed more than one tablet per day. Patients were asked to use at least 12 tablets/attempts at home. Outcome measures were assessed using a global assessment questionnaire (GAQ) ('Did this treatment improve your erections?'). The effect of treatment was assessed every 2 weeks during a 16-week treatment period.
Of the 486 patients re-educated, 56 (11.5%) responded to sildenafil and therefore excluded from the study. The remaining 430 patients were asked to complete the remainder study protocol.
Study protocol
Four hundred and thirty men who were 'nonresponders' to sildenafil entered the study (mean age 41.5 years, range 21-59) with a mean duration of penile ED of 2.8 years (range 1.9-7). All subjects gave their written informed consent before entering Salvage of sildenafil failures with cabergoline MR Safarinejad the study, which was conducted in accordance with the Declaration of Helsinki. The study was not advertised, and no remuneration was offered. This study was carried out without sponsorship. None of the patients had received other treatment for male ED for at least 4 weeks before the start of the study. Patients were eligible for inclusion in the study if they were aged 18 years or older, were nonresponders to sildenafil monotherapy and had medically documented ED to be of at least 6 months duration. The patients had to be in a stable relationship with his wife for at least the previous 6 months.
Exclusion criteria included penile anatomical defects; a primary diagnosis of another sexual disorder; use of psychotropic and antidepressant medication and serious relationship problems; poorly controlled diabetes mellitus; uncontrolled congestive or ischemic heart disease, or renal or liver impairment, a history of alcohol or drug abuse; spinal cord injury; history of prostate cancer, neurological disorders that cause ED, and those unlikely to be available for follow-up.
All patients underwent preliminary assessment, including a medical and sexual history, physical examination, structured interview diagnostic of mental and physical disorders, self-administered International Index of Erectile Function (IIEF), a 15-question, validated measure of ED 44 and intravaginal ejaculatory latency time (IVELT) evaluation. Standard biochemistry and hematological laboratory tests, and measurement of serum testosterone and prolactin levels were also carried out. Men with low testosterone or elevated prolactin levels were not eligible for enrolment.
When indicated, other tests were used to establish the diagnosis of vasculogenic and neurogenic ED, including penile color duplex Doppler ultrasonography before and after intracavernosal injection of 20-mg prostaglandin E 1 , pudendal nerve conduction test and impaired sensory-evoked potentials studies.
Of 430 'nonresponders' 402 met inclusion and exclusion criteria and agree to participate in the study.
Treatments
The patients were randomly assigned to either of two groups of subjects. Randomization was determined by a computer-generated schedule. Group 1 was given 0.5 mg cabergoline (Dostinex; Pharmacia & Upjohn, Milano, Italy) orally weekly initially followed by an increase 0.25 mg biweekly up to 1 mg weekly for 6 months. Group 2 was received a similar regimen of placebo. The placebo was a starch compound with the same color and size of cabergoline. Treatment was administered in a randomized sequence that remained unknown to the patient and to the physician.
All of the men were asked not to consume alcoholic drinks within 6 h of sexual activity. There were no statistical pre-treatment differences in IVELT, IIEF, and mean coitus attempts per week in the 2 groups.
Outcome measures
The effect of treatment was assessed every 2 weeks during treatment and at the end of study. For the analysis of efficacy and safety, all patients were assessed in each visit evaluating changes in IVELT and responses to the questions from the IIEF: question 3, 'When you attempted sexual intercourse, how often were able to penetrate your partner?' and question 4, 'During sexual intercourse, how often were able to maintain your erection to completion of intercourse?' Responses to the two questions were rated on a scale ranging from 1 to 5, with five response options: 1 ¼ almost never/never, 2 ¼ a few times (much less than half the time), 3 ¼ sometimes (approximately half the time), 4 ¼ most times (much more than half the time) and 5 ¼ almost always/always. The five separate response domains, erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction, were also used in the assessment of efficacy. Each patient also responded to a global efficacy question ('Did the treatment improve your erections?'), and maintained an event log, in which was record the date of the medication taken, the presence of sexual stimulation, the hardness of erections on a 4-point scale, the number of attempt at sexual intercourse and the number of attempts that were successful. All patients were asked to indicate their sexual satisfaction on a scale of 0-5 as proposed by Kim and Paick, with 0 being extremely dissatisfied and 5 extremely satisfied. 45 None of the patients underwent formal psychosexual counseling. Patients were given a diary to record the frequency of coitus and adverse drug-related effects and requested to measure IVELT using a stopwatch. Adverse events were recorded at each visit and laboratory tests were monitored throughout the study.
Statistical analysis
Analysis was performed according to the intention to treat. All analysis of significance were two-sided and tested at the 5% level, values of Po0.05 were considered to indicate significant differences. Comparison of sexual satisfaction rates of patients and their wives and comparison of the incidence of side effects were tested using the w 2 test with Yates correction or Fisher's exact, when necessary. The Mann-Whitney test was used to compare quantitative variables. Statistical analysis was performed using the computer statistical package SPSS/4.0 (SPSS, Chicago, IL, USA) and SAS/6.4 (SAS Institute Cary, NC, USA).
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Results
All patients were seen with their partners and interviewed about their sexual activity and patient's erectile function. The wives actively participated in solving their problems. They know everything about the study and were satisfy with it. Four hundred and two patients were recruited, but only 370 (92%) completed the whole randomized trial study (187 of 205 in the cabergoline group and 183 of 197 in the placebo group) (Figure 1 ). At baseline, the study and placebo groups were similar in demographic and clinical characteristics (Table 1) . Thirty-two patients were non-completers. Reasons for non-completion included 14 adverse effects (12 from cabergoline group and two from placebo group), 12 lack of effect on ED (five from cabergoline group and seven from placebo group) and six lost for follow-up (two from cabergoline group and four from placebo group). The difference in dropout rates was not significant between the groups. Mean patient age was 40.5 years (range 21-59) in group 1 and 42.5 (range 21-59) in group 2 (P ¼ 0.1).
Mean patient age was 41.5 years (range 21-59). Mean duration of penile ED was 2.8 years. The etiology of ED was arteriogenic in 132 (35.7%) patients, psychogenic in 28 (7.6%), cavernosal venous leakage in 97 (26.2%), mixed vasculogenic in 105 (28.4%) and secondary to corporeal fibrosis in eight (2.2%). Of the men, 44 (12%) had diabetes mellitus, 192 (52%) were cigarette smokers, 91 (24.6%) had hypercholesterolemia, 87 (23.5%) had hypertension and 52 (14%) had ischemic heart disease.
Efficacy
Treatment with cabergoline was associated with significantly higher scores for question 3 (frequency of penetration) and question 4 (maintenance of erection after sexual penetration) than baseline (P ¼ 0.01) ( Table 2 ). For question 3, the mean score was 3.3 for patients in the cabergoline group compared with 2.0 for those in placebo group, which represent increases from baseline of 45.5% (mean score at baseline, 1.8) and 15% (mean score at baseline, 1.7), respectively. For question 4, the mean score was 3.7 (51.4% increase from baseline mean score of 1.8) for the cabergoline group compared with 2 (20% increase from baseline mean score of 1.6) for the placebo group. At the 6-month end point, 64 Salvage of sildenafil failures with cabergoline MR Safarinejad at sexual intercourse in the cabergoline group as compared with 6% successful attempts during placebo treatment (P ¼ 0.02). Data from patients' event logs showed no evidence of a treatment period effect. Mean scores for the remaining 13 questions of the IIEF are shown in Table 3 . The remaining 13 questions assessing other aspect of male sexual function, showed significant improvements for the cabergoline group compared with the placebo group (P ¼ 0.04). After 6 months of treatment, the IVELT differed significantly between two treatment groups. During the study, from month 1 onward and at the study end point (month 6), there were significant differences between the treatment groups (P ¼ 0.001) ( Table 4 ). The mean pre-treatment IVELT was markedly increased from baseline 98 s in the cabergoline group to 242 s compared with only a gradual and mild increase in the placebo group (from 101 to 116 s) ( Table 4) .
The mean pretreatment intercourse frequency was 1.4 per week for cabergoline compared to 1.2 per week for placebo. Cabergoline demonstrated superiority in increasing mean pretreatment intercourse Cabergoline also increased statistically significant sexual satisfaction scores (P ¼ 0.04) ( Table 4) .
Adverse effects
Adverse effects related to treatment were noted in 12.2% (25/205) of patients taking cabergoline and 2% (4/197) of patients taking placebo (P ¼ 0.001). Of the patients taking cabergoline, 10% reported nausea as an adverse events 2% of patients taking placebo (P ¼ 0.04); 9% taking cabergoline reported headache vs 0% taking placebo (P ¼ 0.001); 9% taking cabergoline reported dizziness vs 2% taking placebo (P ¼ 0.04); and 6% taking cabergoline reported somnolence vs 0% taking placebo (P ¼ 0.03). The cabergoline generally was well tolerated, with side effects noted in 12.2 percent; however, only 5.9 percent had to discontinue treatment.
Discussion
Sildenafil is a novel, orally active agent that has long-term efficacy and safety in treating men with ED of mixed etiology. 46 The approved and worldwide availability of sildenafil has fostered exciting innovative research reports from independent investigators around the world. Despite this pharmacological breakthrough this drug alone is not a solution for all forms of ED. The sildenafil efficacy rate for treating male ED independent of etiology is 65-75%. 47 Steers et al. (1998) reported that only 55 and 59% of patients with severe ED achieved scores of 4 or 5 to IIEF questions 3 and 4, respectively, with 100 mg. sildenafil. 48 Recent reports of tachyphylaxis to sildenafil have also been reported. 49, 50 Attempts at sildenafil salvage by urologists and primary care physicians should be considered as the first step in ED treatment for initial failure. In this study small numbers of nonresponders (11.5%) were responder after re-education. This result is lower than that in other studies that described up to 31, 40 and 55% salvage of sildenafil failures through re-education. 3, 51, 52 The reason for this difference may be proper patient education and evaluation by primary care providers. In our study, 82% of the patients had received adequate administration instructions, and 67% had been scheduled for a follow-up visit. An attempt at sildenafil salvage with re-education is necessary and useful in all patients prior to declaring that treatment has actually failed. According to our results, the main recognized reason for sildenafil failure was lack of effect.
Prior studies have shown that patients preferred oral medical therapies over invasive treatments even prior to the release of sildenafil in 1998. 53, 54 Some men do not respond to PDE-5 inhibitors due to the unknown and known reasons such as concomitant presence of a low androgen milieu. We excluded patients with hypotestosteronemia. The patients may have other different deficiencies such as disorders of penile innervation or neurotransmitter release; malfunction of the enzymes adenylate cyclase or gunalyte cyclase as well as nitric oxide synthase or incompetence of the tunica albuginea. 55 Three systems are recognized as playing a major role in modulating sexual motivation, behavior and function, with both sensory stimulation and copulation-producing dopaminergic activity in all three systems. 56, 57 First, the incerto-hypothalamic dopaminergic system which projects to the medial preoptic area (MPOA) is recognized as one of the most imperative areas for the control of motivational and consummatory aspects of sexual behavior. Particularly, the generation of genital reflexes essential for erection and ejaculation, the focusing of male attention on sexually related stimuli, and the increase of species-specific motor patterns during copulation are controlled by the MPOA. Second system is the mesolimbocortical dopaminergic system (MLC), which originates in the ventral tegmental area and projects to the mesial components of the limbic system (e.g. nucleus accumbens, amygdala, mesial frontal cortex). It has a role in reward processes. The dopaminergic output of the MLC is mainly responsible for appetitive/motivational regulation of sexual activity. This is confirmed by stimulation of MLC DA in response to sexually related sensory stimuli. 58, 59 Finally, the nigrostriatal dopaminergic system (NS), which originates in the substantia nigra and projects primarily to the putamen and caudate nucleus, integrate both sensory and motor aspects of sexual behavior, with NS DA enabling a state of 'preparedness.' Dopaminergic activity of the NS thus contributes to generation of consummatory motor functions, such as the pursuit of a sexual partner before copulation. 60 Cabergoline, an ergot derivative, has been approved for the treatment of hyperprolactinemia in the United States. Cabergoline is a long-lasting D 2 dopaminergic receptor agonist capable of abolishing prolactin secretion with administration once per week, without serious side effects. 61 In healthy young men manipulating hormonal levels to decrease prolactin with cabergoline increases sexual desire and arousal in laboratory conditions. 62 It has been reported that [63] [64] [65] cabergoline could reduce the length of anestrous and induce a fertile estrous period in bitches. Improved penile erections and libido caused by dopaminergic compounds occaSalvage of sildenafil failures with cabergoline MR Safarinejad sionally can be perceived as adverse events. These events, however, can be used to treat ED. With its highly specific D 2 receptor agonism and its favorable adverse event profile, cabergoline may be especially appropriate for this indication. Potential pharmacotherapies will probably require long half-lives or involve methods of administration that provide steady-state delivery over long periods (as in the case of cabergoline). This study employed only a very low dose of cabergoline (up to a maximum of 1 mg/week). Cabergoline doses up to 6 mg/day have been safely used in parkinsonian patients with motor fluctuations, with doses as high as 18 mg/ day being given to particularly severe cases. 66 Higher doses of cabergoline might give greater benefit.
Our investigation showed the efficacy of cabergoline treatment in a group of patients who were unresponsive to sildenafil alone. Cabergoline was associated with a significant increase, with respect to baseline, in the mean-end-of-treatment scores for questions 3 and 4 of the IIEF. Also, 31% of patients taking cabergoline reported that treatment had improved their erections compared with only 7% of those taking placebos.
While improved erectile function is the main goal of ED therapy, quality of life is also enhanced as subjects become more satisfied with sexual activity. We also used an inventory for analysis of satisfaction scores for the men or their wives. Satisfaction scores significantly improved with cabergoline. The notable finding of our study is the superiority of cabergoline over placebo in increasing all of the measured parameters (IVELT, IIEF, and mean number of coitus episodes weekly). Cabergoline provides also significant improvements on the overall sexual functions of the patients with the ED, suggesting that the overall sexual functions of patients with the ED including sexual desire and partner's satisfaction have improved.
Our study demonstrates that about one-third of nonresponders to sildenafil can be 'salvaged' with cabergoline monotherapy therapy. A response was achieved by 36.4% (48 of 132) of patients with arteriogenic ED, 28% (27 of 97) with cavernosal venous leakage and 35.2% (37 of 105) with mixed vasculogenic ED. The responses were significantly higher for patients with psychogenic ED (75%). Patients with cavernosal venous leakage appeared less likely to respond to cabergoline monotherapy. None of the patients with corporeal fibrosis had response to cabergoline.
Clearly our study group comprised a highly select subset of patients with severe vasculogenic erectile None of the 54 patients with cavernosal venous leakage and a flow to maintain rate of X30 ml/min had score of 3 to both questions, whereas 27 of 43 with cavernosal venous leakage and flow to maintain rate of o30 ml/min achieved this score. None of the patients with peak systolic velocity p20 cm/s were responder to cabergoline. Of the 370 patients 44 (12%) had diabetes mellitus and 230 (62%) had two or more vascular risk factors in addition to diabetes. Forty four patients were diabetic. Improved erections were reported by only 51-57% of patients with diabetes mellitus treated with sildenafil. 67, 68 Of 44 nonresponders to sildenafil, 12 (27.3%) responded to cabergoline. None of these responders had severe vasculogenic concomitant risk factors.
None of our patients had a history of spinal cord injury, pelvic trauma or surgery, neurological and disorders that cause ED.
Severe vascular lesions as arterial insufficiency or cavernovenous leakage are significant factors influencing response to cabergoline treatment. The erectile response is more dependent on the efficacy of the corporeal veno-occlusive mechanism. Our findings parallel the results already described as we have 78% of these sildenafil nonresponders with this problem. 69, 70 Our study clearly demonstrates that ED patients did receive appropriate education in the use of the prescribed medication, as well as they are also adequately followed-up.
Cabergoline is a potent 5-HT receptor activator. 35 The serotonergic system has a crucial role on ejaculation function. Serotonin reuptake inhibitors have all been shown to be effective in the treatment of premature ejaculation. [71] [72] [73] [74] This study demonstrated that cabergoline 1 mg weekly significantly delay ejaculation in men. Furthermore, mean weekly intercourse episodes for patients treated with cabergoline compared to placebo were significantly superior. We also used an inventory for analysis of satisfaction scores for the men or their wives. While improved erectile function is the main goal of ED therapy, quality of life is also enhanced as subjects become more satisfied with sexual activity. In this study, satisfaction scores were numerically better throughout the therapy period in subjects who received cabergoline vs placebo, and by month 6 such improvements were statistically superior in cabergoline-treated subjects.
Cabergoline was well tolerated with only 12 patients (5.9%) discontinuing on account of adverse event. There were no unexpected adverse events associated with cabergoline. The dropout rate in the cabergoline group was 9.3%, and the dropout rate in the placebo group was 5.6%. In our opinions a diagnostic work-up is still mandatory in the medical care process of impotent patients, especially when co-morbidity is present.
The results of this analysis indicate that cabergoline, administered once weekly at a maximum dose of 1 mg/week has therapeutic efficacy in the onethird of nonresponders to sildenafil. Whether initial treatment with cabergoline in de novo cases of ED will increase the success rate, remains undetermined. A limitation of our study is that we were 
Conclusions
These findings indicate that there is sufficient evidence to proceed with a larger-sized trial of cabergoline for ED. These data also support a management strategy of an oral medical therapy trial regardless of baseline sexual function or the etiology of ED. Future researches addressed to discover new targets acting on alternative pathways controlling sexuality and preventing vascular damage to the penis is warranted.
